About
Chiasma is a clinical late-stage biopharmaceutical company focused on improving the lives of patients with rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop and ultimately commercialize oral medications that are currently available only as injections. Chiasma is evaluating proteins, peptides, and small molecule drugs that are currently available only by injection but which could potentially be converted to oral delivery using the companys TPE technology. In June 2020, the company received FDA approval for its MYCAPSSA (octreotide) capsules for long-term maintenance treatment in patients with acromegaly. MYCAPPSA is a treatment for chronic acromegaly that can be taken orally in pill form rather than by injection. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. In August 2021, Chiasma was acquired by Amryt , a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.